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Background: The Declaration of Helsinki, the World Medical Association’s (WMA’s) statement of ethical
guidelines regarding medical research, is published in the three official languages of the WMA: English,
French and Spanish.
Methods: A detailed comparison of the three official language versions was carried out to determine ways in
which they differed and ways in which the wording of the three versions might illuminate the interpretation of
the document.
Results: There were many minor linguistic differences between the three versions. However, in paragraphs 1,
6, 29, 30 and in the note of clarification to paragraph 29, there were differences that could be considered
potentially significant in their ethical relevance.
Interpretation: Given the global status of the Declaration of Helsinki and the fact that it is translated from its
official versions into many other languages for application to the ethical conduct of research, the differences
identified are of concern. It would be best if such differences could be eliminated but, at the very least, a
commentary to explain any differences that are unavoidable on the basis of language or culture should
accompany the Declaration of Helsinki. This evidence further strengthens the case for international
surveillance of medical research ethics as has been proposed by the WMA.
O
ne issue that has almost completely escaped mention in
the debate on a global consensus on bioethical issues is
the difficulty presented by linguistic barriers. Here we
consider this issue in relation to the Declaration of Helsinki
(DoH). This document has been central to the World Medical
Association’s (WMA’s) efforts to achieve consensus on the
ethical conduct of medical research and arguably remains the
most important international document in this field.1 2
Reiterating the organisation’s efforts, the Director of Ethics at
the WMA, Dr John Williams, has recently issued the challenge
that ‘‘every effort should be made to internationalise bioethics’’.3
Indeed, the challenge of addressing differing ethical standards for
research in different parts of the world formed one of the driving
forces for the revision of the DoH in the first place.4 That these
issues are still a flashpoint for controversy is amply illustrated in a
review of the film version of John Le Carre’s novel The Constant
Gardener, written by Marcia Angell, whose 1997 editorial (in The
New England Journal of Medicine) helped ignite the controversy.5
The book and film portray the fictional nefarious actions of a
multinational pharmaceutical company. However, Angell uses
the opportunity of the review to state again her concerns that
medical research standards may differ between countries, and, in
particular, that the standards of protection for research subjects
are lower in developing countries, and that some researchers
continue to exploit these lower standards to conduct studies that
would not be ethically permissible in the sponsoring country.
In its most controversial paragraphs (paragraphs 29 and 30),
the DoH has sought to address aspects of this issue. The
ensuing uproar was such that 4 years of debate culminated first
in the note of clarification to paragraph 29 in 2002 and later in
the note of clarification to paragraph 30 in 2004.6
Yet it also stands to reason that if international statements of
ethical standards vary in their content across different language
versions, this will be an additional impediment to the achieve-
ment of consistent international standards. We raise this question
with respect to the DoH primarily because of the document’s
international prominence and its controversial attempts to go to
the heart of these continuing ethical controversies. It also should
be pointed out that because the DoH is relatively succinct at less
than 2000 words,7 and exists in only three official languages
(compare, for example, the European Union Clinical Trials
Directive, which is much longer and must be translated into the
20 official languages of the European Union), it is a less unwieldy
starting point for this analysis.
The DoH exists in three official versions, one in each of the
official languages of the WMA (English, French and Spanish).6 8 9
The WMA is the largest global grouping of medical professionals
and currently numbers the National Medical Associations of
more than 80 nations as its members.10 Eventually, the DoH will
be translated from the official versions into a multiplicity of
different languages, and will then likely go on to influence the
wording of many other documents, so internationally the stakes
are high. The WMA gives no guidance on such further translation
and it is up to the organisation that is arranging a translation as to
which official version or versions to use as their baseline, and the
accuracy of such further translations remains the responsibility of
that individual or other organisation.
METHODS
We undertook a detailed comparison of the English, French and
Spanish versions of the DoH. In each case, this was initially
undertaken by doctors on our authorship team who grew up in
contexts where they were fluent in both of the languages (NHG
for the French–English comparison and LMP for the Spanish–
English comparison) and who have used both of the relevant
languages extensively in a professional context. To reduce the
subjectivity involved in this process, we obtained three
translations of each of the French and Spanish versions of
the DoH into English. The translators were all language
Abbreviations: DoH, Declaration of Helsinki; WMA, World Medical
association
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teachers and were not previously aware of the content of the
DoH. These back-translations were used to verify the differ-
ences detected on initial analysis. Full texts of these transla-
tions are available through a separate internet link.11
RESULTS
A detailed comparison of the English, French and Spanish texts
of the DoH reveals, not unexpectedly, many grammatical and
stylistic differences between the versions. Although in many
cases these changes were not dictated by rules of language
syntax or any obvious aesthetic advantage, most differences did
not affect meaning. For example, in paragraph 5, the English
and Spanish versions state, ‘‘In medical research on human
subjects, considerations related to the well-being of the human
subject should take precedence over the interests of science and
society’’. The French version reverses the syntactic logic; ‘‘In
medical research on human subjects, the interests of science
and society should never take precedence over the well-being of
the human subject’’.
The main concern of our discussion, however, is the small
number of paragraphs where something important seems to be
‘‘lost in translation’’. Here we outline five that we consider of
particular importance.
(1) True opposites or a risky assumption? (paragraph 1)
The English and Spanish versions use ‘‘identifiable’’, whereas
the French version states ‘‘non-anonymes’’ (non-anonymous)
to define the kinds of studies using data or tissue samples that
are covered by the DoH guidelines (table 1). Ethical dimensions
regarding protection of privacy of personal information in
epidemiological and tissue sample studies have long been an
issue for debate, but the 2000 revision is the first occasion when
the DoH has explicitly referred to such issues.7 12 The question
of an ethically relevant difference in meaning hinges around
whether there is any difference between ‘‘non-anonymous’’
and ‘‘identifiable’’, or put another way, whether ‘‘identifiable’’
and ‘‘anonymous’’ are exact opposites of one another. Clearly, if
the researchers know the identity of the research subject, then
data are ‘‘identifiable’’. On the other hand, if all possible re-
linking of data with the person providing the data has been
eliminated, then data are ‘‘anonymous’’. What about the
intermediate situation where a code held by a third party
separates the identity of an individual from the data used by
the researcher? These would seem to be ‘‘non-anonymous’’ in
that, if the right steps were taken, individual and data could be
re-linked. But are they ‘‘identifiable’’? Certainly they are not
identifiable to the researchers and this may be considered to be
the ethically important point. So we see that a grey area
emerges that could possibly lead to different interpretations of
the French version from the Spanish and English versions.
Given that ‘‘non-anonymous’’ would be perfectly acceptable in
the English version (and ‘‘no ano´nimo’’ in the Spanish), or that
‘‘identifiables’’ would be a valid adjective to use in the French
version, we argue that this difference is unnecessary under the
rules of the languages concerned and introduces an unneces-
sary risk of an ethically relevant difference in interpretation.
(2) Whatever happened to ‘‘quality’’? (paragraph 6)
Without explanation, the French version omits the word
‘‘quality’’ from the list of criteria by which medical methods
should be evaluated (table 2). This is of particular concern
because internal discussions subsequent to the adoption of the
2000 version of the DoH raised concerns that ‘‘safety’’ was not
explicitly included in this list. It was concluded by the WMA’s
Medical Ethics Committee in May 2002 that ‘‘the aspect of
safety is sufficiently addressed by the term ‘quality’, which is
already mentioned in paragraph 6’’.13
(3) Three languages, three standards in the control arm?
(paragraph 29)
This paragraph (table 3), along with paragraph 30 (discussed
below), has been one of the most controversial in the DoH. Both
of these paragraphs, after lengthy word-by-word debate about
their meaning, have had notes of clarification appended to
them. In paragraph 29, a major controversy relates to the
appropriate standard of comparator in an active-control trial.
Should it be the best available anywhere in the world or the
best that was available to the population in which the trial was
conducted?14 The change from ‘‘best current’’ (English) to ‘‘best
existing’’ (‘‘mejores existentes’’ in Spanish) and ‘‘in use’’ (‘‘en
usage’’ in French) is arguably the most significant difference
we discovered between the three versions. Although we
recognise that there may be semantic overlap, the French ‘‘en
usage’’ carries some implication of a localised availability.
However, the 1996 French version used the word ‘‘courantes’’
(‘‘current’’) in the paragraph dealing with placebo and the
change to ‘‘en usage’’ paradoxically seems to move the
translation further away in potential meaning. On the other
hand, the Spanish version is suggestive of a universal standard
of care for the control group. The debate over the standard of
comparator arm is not fully resolved. In this paragraph, the
difference between the three language versions illuminates the
debate but, of course, does not resolve it.
Table 1 The three official versions of second sentence of paragraph 1
English6 French8 Spanish9
1. … Medical research involving human
subjects includes research on identifiable
human material or identifiable data.
1. … Celle-ci comprend e´galement les e`tudes
re´alise´es sur des donne´es a` caracte`re personnel
ou des e´chantillons biologiques non-anonymes
1. La investigacio´n me´dica en seres humanos incluye la
investigacio´n del material humano o de informacio´n
identificables.
Table 2 The three official versions of the second sentence of paragraph 6
English6 French8 Spanish9
6. …Even the best proven prophylactic,
diagnostic, and therapeutic methods must
continuously be challenged through research
for their effectiveness, efficiency, accessibility
and quality
6. …Les me´thodes diagnostiques, the´rapeutiques
et de pre´vention, meˆme les plus e´prouve´es, doivent
constamment eˆtre remises en question par des
recherches portant sur leur efficacite´, leur efficience
et leur accessibilite´
6. …Incluso, los mejores me´todos preventivos,
diagno´sticos y terape´uticos disponibles deben ponerse a
prueba continuamente a trave´s de la investigacio´n para
que sean eficaces, efectivos, accesibles y de calidad.
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(4) Differing standards for use of placebo controls?
(note of clarification to paragraph 29)
The English version, in the second of the two clauses defining
acceptable conditions for the use of placebo where proven therapy
exists, makes the requirement that there be no ‘‘additional risk of
serious or irreversible harm’’ (table 4). In the French version, we
find ‘‘des risques supple´mentaires de dommages significatifs ou
durables’’. ‘‘Durables’’, which translates most closely as ‘‘long-
lasting’’, would seem to have a different meaning from
‘‘irreversible’’. The adjective ‘‘irre´versible’’ is available in French,
or the English could be changed to ‘‘long-lasting’’ depending on
what the intent is. The Spanish version uses ‘‘irreversible’’.
However, the ethical demand does need clarifying. If a harmful
outcome of a study potentially lasted several years (but was
eventually reversible), would that really be acceptable? Our
suggestion is that it would not and therefore that either the
French version is preferable, or all three versions should refer to
‘‘long-lasting or irreversible’’ in this paragraph.
(5) Requiring the impossible? (paragraph 30)
This paragraph (table 5) has also been the subject of considerable
controversy and, in October 2004, had a note of clarification
appended.6 8 9 The English version calls for patients to be ‘‘assured
of access’’, whereas the French requires that patients be ‘‘assured
of benefit’’. This seems to be beyond what any ethical code can
require. It is only the potential benefit (through assurance of
access) that can be required. Perhaps a wording that combines
the two versions could read ‘‘should be assured of access to the
potential benefit of…’’. The note of clarification to paragraph 30,
added in 2004, may partially address this problem by speaking of
‘‘access’’ (acce`s) rather than benefit, but the difficulty with the
wording of the paragraph itself still stands.
‘‘Must’’ or ‘‘should’’?
Debate continues about whether normative ethical guidelines
such as the DoH, which do not have the status of legal documents,
are best seen as pragmatic (and thus able to be followed in every
case) or as aspirational (thus setting the direction but recognising
that not every case will achieve every aspiration). Interestingly,
the versions may differ in this regard. The Spanish (‘‘deber’’, and
its conjugates, rather than the conditional ‘‘deberia’’) and French
(‘‘doivent’’ and its conjugate ‘‘doit’’ rather than ‘‘devrait’’)
consistently use words more closely equating to ‘‘must’’.
English, on the other hand, uses ‘‘should’’ 16 times and ‘‘must’’
5 times where the Spanish ‘‘deber’’ and French ‘‘doit’’ are used.
The one exception is paragraph 4 of the DoH where the English
(‘‘research … must rest in part on…’’) is translated in French as
‘‘peuvent imposer de recourir’’ (ie, ‘‘may require recourse to…’’).
However, this sentence could be considered descriptive of a fact
rather than a statement of an ethical guideline and thus is not a
true exception to the statement above.
It is not possible simply by analysing the text to understand
what to make of this, eg, whether the Francophone or
Hispanophone worlds see a set of normative ethics differently
from the Anglophone world. Nor is it clear why the English
version switches between ‘‘should’’ and ‘‘must’’. Further
conjecture is therefore beyond the scope of this paper. It
remains, however, an intriguing difference that should be
explored in further studies.
DISCUSSION
Guidelines for WMA translations are not published. However, both
Dr Delon Human, the Secretary-General of the WMA at the time of
the revision, and Dr John Williams, the current Director of Ethics at
the WMA, affirm that the translations should be as close as possible
to one another, recognising that some differences may be imposed
by the syntactical rules or the cultural framework of the languages
(Personal communications, 2004). Translation difficulties are an
enormous communications challenge faced by any establishment
dealing with people who speak different languages, and the WMA
is no exception. We accept that there are complex philosophical and
linguistic questions about the nature of language, translation and
meaning that remain among the biggest issues in contemporary
philosophy.15 16 Steiner asserts, ‘‘each human language maps the
world differently’’.17 This is a simplified statement of a well-
recognised theory within the study of linguistics and anthropology
known as theSapir-Whorf hypothesis,which contends that culture
and ethics are so bound up in the language used that they can only
be fully understood from within that linguistic system.18 To the
extent that this is true, not only will the translations always contain
differences, but also some differences will never be apparent to
those trying to investigate them.
On the other hand, as Peter Kay has pointed out, cultural
differences may be much more significant than linguistic
differences and may lead to very different world views between
speakers of the same language.19 This is especially relevant in
view of the worldwide distribution of the three official WMA
languages: Spanish would be an important language for ethical
discourse in settings as diverse as Madrid, Montevideo and
Havana, French in Port-au-Prince, Paris and Montreal, and
English in Glasgow, Gabarone and Auckland.
Table 3 The three official versions of the first sentence of paragraph 29
English6 French8 Spanish9
29. The benefits, risks, burdens and effectiveness
of a new method should be tested against those
of the best current prophylactic, diagnostic, and
therapeutic methods. …
29. Les avantages, les risques, les contraintes
et l’efficacite´ d’une nouvelle me´thode doivent eˆtre
e´value´s par comparaison avec les meilleures
me´thodes diagnostiques, the´rapeutiques ou de
pre´vention en usage. …
29. Los posibles beneficios, riesgos, costos y eficacia de
todo procedimiento nuevo deben ser evaluados mediante
su comparacio´n con los mejores me´todos preventivos,
diagno´sticos y terape´uticos existentes. …
Table 4 The three official versions of the relevant portion of the note of clarification to paragraph 29
English6 French8 Spanish9
…where a prophylactic, diagnostic or therapeutic
method is being investigated for a minor condition
and the patients who receive placebo will not be
subject to any additional risk of serious or
irreversible harm.
…lorsqu’une me´thode prophylactique, diagnostique
ou the´rapeutique est mise a` l’essai pour une affection
be´nigne et que la participation a` l’essai n’expose
pas a` des risques supple´mentaires de dommages
significatifs ou durables.
...Cuando se prueba un me´todo preventivo,
diagno´stico o terape´utico para una enfermedad
de menos importancia que no implique un riesgo
adicional, efectos adversos graves o dan˜o
irreversible para los pacientes que reciben el placebo.
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Some might argue that there is no empirical evidence for
differing standards as a result of these translation issues within
the DoH. We invite those who would contend this to consider
both the difficulty in gathering such evidence (given linguistic
difficulties), the long time-frame before those differences
would be noticed empirically, and most importantly to consider
whether we really want to find out about such systematic
differences after the fact.
It is by no means our intention to suggest that any of the three
official languages should become dominant in determining the
wording of the DoH, or in any other debate regarding issues of
international importance in medical research ethics. One of the
major drawbacks of our study is that analysis of the results has
been in English only. Ultimately, in the absence of a universal
language, there is no way around the fact that discussions of
meaning must take place in one language or another. The use of
English is dictated by the provenance of this work.
The existence of discrepancies that could lead to a difference in
interpretation is worrying. That we have demonstrated the
existence of such discrepancies in the case of the relatively
succinct DoH, across only three languages, gives rise to questions
about other key international documents that are longer and have
many more official language versions. So what is to be done?
In the first instance, the WMA should address these differences
either by way of explanation or by way of the necessary
amendments to the DoH to harmonise their meaning. Given
the intense word-by-word debate and analysis that occurs both in
WMA meetings and in the subsequent literature about the DoH,
attention to these differences between the three official versions
is vital. The DoH remains too significant an international
instrument to leave these inconsistencies unattended.
On a broader note, however, this study shows one possible
source of variation in ethical practice regarding research in
different parts of the world. It raises the much bigger question
of how to detect and act upon research standards that vary in
unacceptable ways in different geographical settings (we accept
that some variations, eg, greater emphasis on verbal consent
than on written consent in different cultures, may be
acceptable). One possible way forward was suggested by Dr
Kgosi Letlape of South Africa, currently president of the WMA,
when he made his speech as president-elect in Tokyo in October
2004. Dr Letlape mooted the creation of a surveillance unit to
monitor coherence with the standards of research in various
parts of the world.20 Unfortunately, this aspect of his speech
was neither reported in the written summary,21 nor does it
appear to have been taken any further by the WMA.
The last 50 years has seen the widespread recognition of two
lines of defence for protection of people participating in
research: voluntary participation through appropriate consent
and the establishment of independent ethical review commit-
tees. What is lacking now, especially in the context of
increasing multinational studies, is some system to ensure that
standards worldwide do not fluctuate outside ethically accep-
table parameters of variation. Dealing with the issue of
linguistic harmonisation of ethical guidelines would ideally fit
within the work of such a surveillance unit. However,
harmonisation of the three official versions of the DoH need
not, and should not, wait for its establishment.
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Table 5 The three official versions of paragraph 30
English6 French8 Spanish9
30. At the conclusion of the study, every patient
entered into the study should be assured of
access to the best proven prophylactic, diagnostic
and therapeutic methods identified by the study.
30. Tous les patients ayant participe´ a` une e´tude
doivent eˆtre assure´s de be´ne´ficier a` son terme des
moyens diagnostiques, the´rapeutiques et de
pre´vention dont l’e´tude aura montre´ la supe´riorite´.
30. Al final de la investigacio´n, todos los pacientes
que participan en el estudio deben tener la certeza
de que contara´n con los mejores me´todos preventivos,
diagno´sticos y terape´uticos probados y existentes,
identificados por el estudio.
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